中文

Events

Doer Biologics Completes First Patient Dosing in Phase II Clinical Trial of DR10624 for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) / Metabolic Dysfunction-Associated Steatohepatitis (MASH)

2025/04/22

Read more

Doer Biologics Completes Patient Enrollment in Phase II Clinical Study of DR10624 for Severe Hypertriglyceridemia

2025/03/10

Read more

World's First Triple Agonist DR10624 Completes Full Enrollment in Phase 1b/2a Clinical Trial for Obesity with Hypertriglyceridemia

2024/07/09

Read more

Zhejiang Doer Biologics Announces License Agreement with BioNTech

2023/07/11

Read more

Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD

2022/12/16

Read more

Doer Biologics signs licensing agreement with Lonza to develop multi-specific biotherapeutics using XS Pichia

2022/12/09

Read more

Doer Biologics CEO invited as speaker at BIT 2021

2021/04/10

Read more

Doer Biologics won the honor of the first "Qiantang Leading Talent Team" in the new district

2020/12/17

Read more

Doer Biologics Received nearly 100 millions of RMB in A+ round of financing to promote the research of multispecific innovative biologics

2020/11/02

Read more

Doer Biologics Attended the Conference of “Biopharma Development & Production 2018” in Shanghai

2018/05/23

Read more